Sunshine Biopharma Inc. (SBFM) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Sunshine Biopharma Inc. operates as a pharmaceutical company with two primary business segments: (1) Nora Pharma Inc., a Canadian subsidiary marketing 70 generic prescription drugs, and (2) Sunshine Biopharma Canada Inc., which develops and sells over-the-counter (OTC) supplements. The company is also engaged in proprietary drug development, specifically K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections. The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue (Sales) | $8,901,341 | $7,541,046 |
| Gross Profit | $2,730,426 | $2,354,337 |
| Gross Margin | 30.7% | 31.2% |
| Net Loss | $(1,179,771) | $(1,283,801) |
| Loss Per Share (Basic & Diluted) | $(0.44) | $(2.00) |
| Cash and Cash Equivalents | $8,124,610 | $17,434,208 (End of Q1 2024) |
| Operating Cash Flow | $(1,713,835) | $(3,185,158) |
| Total Debt / Liabilities | $6,484,635 | $7,059,638 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased by 18.0% ($1.36M) year-over-year, driven by new product launches and expanded marketing efforts in the Canadian generic drug market.
- Expense Management: While General & Administrative (G&A) expenses rose by $321,250 (8.7%), this was offset by significant reductions in legal fees ($194,799 decrease) and accounting fees ($58,247 decrease). Increases were noted in consulting fees (+$317,886) and marketing (+$200,315).
- Profitability: The net loss narrowed by approximately $104,000 compared to Q1 2024. The loss per share improved significantly from $(2.00) to $(0.44), largely due to a substantial increase in the weighted average shares outstanding (from 641,310 to 2,703,293) following reverse stock splits and warrant exercises.
- Liquidity: Cash reserves decreased by approximately $1.55M during the quarter, primarily due to operating cash outflows and investing activities, though operating cash burn improved significantly compared to the prior year.
Outlook, Risks, and Unusual Items
- Guidance & Outlook: Management projects that existing cash plus sales revenue will fund operations for the next 24 months. The company aims to reduce the cost of goods sold from ~70% to 60% to reach breakeven. They anticipate needing additional capital in the future for R&D and clinical trials.
- Subsequent Events (Post-March 31, 2025):
- Financing: On April 3, 2025, the company completed a registered direct offering raising approximately $2.46M gross ($1.83M net). On April 2, 2025, warrant exercises generated $1.84M in proceeds.
- Legal Contingency: On April 14, 2025, the company terminated the employment of Mr. Malek Chamoun (President of Nora Pharma). On April 17, 2025, the company received a demand letter from Mr. Chamoun's attorneys requesting $7,307,025 CAD (~$5.3M USD). The company considers these demands unfounded and intends to defend vigorously.
- Risks: The company faces risks related to Canadian government drug pricing policies (pCPA negotiations), the success of proprietary drug development (currently in animal testing), and the potential impact of the pending legal dispute with the former subsidiary president.
Investor Verification Checklist
- Legal Exposure: Verify the status of the $5.3M demand letter from the former Nora Pharma president and the company's legal defense strategy.
- Cash Runway: Confirm the updated cash runway following the April 2025 financing events and the impact of the potential legal settlement on liquidity.
- Cost Reduction Targets: Monitor progress on the stated goal to reduce Cost of Goods Sold (COGS) from 70% to 60% to achieve breakeven.
- Warrant Dilution: Review the adjusted terms of the Series B Warrants (exercise price adjusted to $2.07) and the potential for further dilution from the 15.5M+ outstanding warrants.
- R&D Milestones: Track the transition of K1.1 mRNA and SBFM-PL4 from animal testing to potential clinical trial phases.